Model
|
M1
|
M2
|
M3
|
S1
|
S2
|
---|
Model description
|
Aggregate data only
|
IPD and aggregate with no covariate adjustments
|
IPD and aggregate with covariate adjustments
|
Down-weighted observational studies
|
Constructed control arms
|
---|
α
i
, Jacobs 2009
|
4.77 (-18.60,29.12)
|
4.55 (-19.07, 29.45)
|
4.39 (-18.77, 28.59)
|
4.07 (-17.16, 26.84)
|
−1.10 (-22.54, 17.77)
|
α
i
, (imatinib to ERA + PDE5i)
|
4.27 (-14.13, 22.59)
|
3.63 (-10.57, 17.78)
|
3.50 (-10.59, 17.69)
|
3.55 (-9.78, 17.12)
|
0.93 (-11.93, 14.71)
|
α
(mean of
α
i
s)
|
4.78 (-4.77, 14.60)
|
4.39 (-5.14, 14.80)
|
4.30 (-4.73, 14.17)
|
3.99 (-4.87, 13.68)
|
0.02 (-8.74, 8.78)
|
π
1
(AGE)
|
NA
|
NA
|
−0.90 (-1.52, -0.27)
|
−0.90 (-1.52, -0.27)
|
−0.89 (-1.53, -0.26)
|
π
3
(STATUS)
|
NA
|
NA
|
−11.89 (-28.20, 4.44)
|
−11.92 (-28.29, 4.36)
|
−12.02 (-28.64, 4.60)
|
π
5
(PVR)
|
NA
|
NA
|
−0.05 (-0.70, -0.02)
|
−0.05 (-0.07, -0.02)
|
−0.05 (-0.07, -0.02)
|
β
6
(Pr to ERA + PDE5i)
|
35.98 (-44.15, 114.70)
|
35.16 (-43.81, 113.80)
|
34.65 (-42.18, 113.20)
|
22.64 (-168.30, 217.00)
|
40.65 (-37.09, 117.80)
|
β
8
(imatinib to ERA + PDE5i)
|
39.09 (2.72, 75.80)
|
39.91 (11.31, 68.36)
|
40.06 (13.38, 67.67)
|
39.40 (13.83, 66.03)
|
42.62 (15.18, 69.79)
|
(β
8
− β
6
) imatinib v Pr to ERA + PDE5i
|
3.11 (-83.70, 89.27)
|
4.75 (-77.88, 87.10)
|
5.41 (-76.65, 85.24)
|
16.76 (-179.26, 209.80)
|
1.97 (-78.62, 83.53)
|
- Results sampled from 250000 iterations following a burn-in of 100000.